FindTrial
Sign In

Saliva-based EGFR mutation detection in non small cell lung cancer patients using EFIRM Technology

Saliva-based EGFR mutation detection in lung adenocarcinoma patients using EFIRM Technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-16009853
Enrollment
Unknown
Registered
2016-11-14
Start date
2016-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Gold Standard:
Index test:

Sponsors

Shanghai Pulmonary Hospital, Tongji University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years; 2. Lung adenocarcinoma patients with pathological diagnosis; 3. Voluntary participate the clinical research and sign on the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of other malignancy within 5 years; 2. Patients had the history of systemic anti-cancer treatment within 5 years; 3. Patients with severe primary diseases, such as heart, brain, kidney and hematopoietic diseases; 4. Women in pregnancy and lactation; 5. Patients who had known their gene mutations; 6. Patients who are participating in other clinical trials; 7. Patients with poor compliance or other situations the researchers believe that is not eligible for inclusion.

Design outcomes

Primary

MeasureTime frame
the sensitivity and specificity of saliva-based EGFR mutation detection;—

Countries

China

Contacts

Public ContactLixia Ju

Shanghai Pulmonary Hospital, Tongji University School of Medicine

jvlixia@126.com+86 13641839305

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026